LOUISVILLE, Ky., May 01, 2026 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. ("BrightSpring" or the "Company") (NASDAQ: BTSG), a leading provider of home and community-based health services for complex populations, today announced financial results for the first quarter ended March 31, 2026, and increased full year 2026 Revenue and Adjusted EBITDA(1) guidance.
First Quarter 2026 Financial Highlights
(note: all figures represent continuing operations and exclude the Community Living business)
-- Net revenue of $3,614 million, up 25.6% compared to $2,878 million in the
first quarter of 2025
-- Gross profit of $482 million, up 42.5% compared to $338 million in the
first quarter of 2025
-- Net income of $74 million compared to $9 million in the first quarter of
2025
-- Adjusted EBITDA1 of $190 million, up 44.8% compared to $131 million in
the first quarter of 2025
-- Leverage2 of 2.27x as of March 31, 2026, compared to pro forma leverage3
of 2.60x on December 31, 2025, both of which exclude the impact of the
Community Living divestiture
-- Divestiture of Community Living business to Sevita closed on March 30,
2026, which resulted in a $31.2 million gain on sale, net of tax recorded
within discontinued operations
-- Completion of an underwritten secondary offering of our common stock by
affiliates of Kohlberg Kravis Roberts & Co. L.P. and certain members of
management in March 2026, and a concurrent $60.0 million repurchase of
1,464,807 shares of common stock from the underwriter
"We are pleased with the Company's first quarter results, which reflect the team's commitment to patients as well as the operating and growth priorities discussed at the Investor Day in March," said Jon Rousseau, Chairman, President, and Chief Executive Officer of BrightSpring. "Our focus continues to be anchored in operational and commercial best practices across the organization while leveraging scale to provide quality and effective services to complex patient populations. As we look ahead to the remainder of 2026, we are focused on growing each of our businesses while executing against our goals and reaching more patients who can benefit from these highly impactful and valuable services."
(1) Adjusted EBITDA is a non-GAAP financial measure. Please see "Non-GAAP Financial Information" at the end of this press release for a reconciliation of Adjusted EBITDA to net income from continuing operations, the most directly comparable financial measure prepared in accordance with GAAP.
(2) The results of the Community Living business are excluded in the calculation of our leverage pursuant to the terms of our First Lien Credit Agreement since the Company divested the Community Living business prior to the end of the period.
(3) Leverage is presented on a pro forma basis assuming the Community Living divestiture closed as of December 31, 2025.
Key Financials(4) (for BrightSpring continuing operations)
Three Months Ended
March 31, (Unaudited)
--------------------------- ------
2026 2025 %
------------- ------------ ------
($ in millions)
Pharmacy Solutions Revenue $ 3,171 $ 2,532 25%
Provider Services Revenue 442 346 28%
--------- --------
Total Revenue $ 3,614 $ 2,878 26%
========= ========
Three Months Ended
March 31, (Unaudited)
------------------------------- ------
2026 2025 %
----------- ---------- ------
($ in millions)
Pharmacy Solutions segment
EBITDA $ 169 $ 116 46%
Provider Services segment
EBITDA 66 51 29%
--- ------ ------
Total Segment Adjusted EBITDA $ 235 $ 167 41%
Corporate Costs (45) (36) -
--- ------ ------
Total Company Adjusted
EBITDA(1) $ 190 $ 131 45%
=== ====== ======
Business Metrics
Three Months Ended
March 31, (Unaudited)
-------------------------- ------
2026 2025 %
-------------- ---------- ------
Pharmacy Solutions
Prescriptions dispensed 10,729,876 10,877,294 (1%)
Revenue per script ($) 295.56 232.79 27%
Gross Profit per script ($) 28.03 18.75 50%
Provider Services
Home Health Care average daily
census 46,066 30,241 52%
Rehab Care persons served 7,620 6,697 14%
Personal Care persons served 16,079 15,863 1%
(1) Adjusted EBITDA is a non-GAAP financial measure. Please see "Non-GAAP Financial Information" and the end of this press release for a reconciliation of Adjusted EBITDA to net income from continuing operations, the most directly comparable financial measure prepared in accordance with GAAP.
(4) Financial tables may not foot due to rounding.
Full Year 2026 Financial Guidance
For the full year 2026, BrightSpring is increasing Revenue and Adjusted EBITDA guidance, which excludes the Community Living business and the effects of any future closed acquisitions. All growth rates are shown as compared to the full year 2025 Revenue and Adjusted EBITDA results, excluding the Community Living business:
-- Revenues of $14,725 million to $15,225 million, or 14.1% to 17.9% growth.
-- Pharmacy Segment Revenue of $12,850 million to $13,300 million, or
12.3% to 16.2% growth.
-- Provider Segment Revenue of $1,875 million to $1,925 million, or
28.0% to 31.4% growth.
-- Total Adjusted EBITDA5 of $795 million to $825 million, or 28.7% to 33.6%
growth.
-- The Amedysis and LHC acquisition is expected to contribute approximately
$30 million in Adjusted EBITDA in 2026.
(5) A reconciliation of the foregoing guidance for the non-GAAP metric of Adjusted EBITDA to GAAP net income from continuing operations cannot be provided without unreasonable effort because of the inherent difficulty of accurately forecasting the occurrence and financial impact of the various adjusting items necessary for such reconciliation that have not yet occurred, are out of our control, or cannot be reasonably predicted. For the same reasons, the Company is unable to assess the probable significance of the unavailable information, which could have a material impact on its future GAAP financial results.
Webcast and Conference Call Details
The Company will host a conference call today, May 1(st) at 8:30 a.m. Eastern Time. Investors interested in listening to the conference call are required to register online.
A live and archived webcast of the event will be available on the "Events & Presentations" section of the BrightSpring website at https://ir.brightspringhealth.com/. The Company has posted supplemental information on the first quarter 2026 results that it will reference during the conference call. The supplemental information can be found under the "Events & Presentations" on the Company's investor relations page.
About BrightSpring Health Services
BrightSpring Health Services provides complementary home- and community-based health solutions for complex populations in need of specialized and/or chronic care. Through the Company's service lines, including pharmacy, home health care, and rehabilitation, we provide comprehensive and more integrated care and clinical solutions in all 50 states to over 475,000 customers, clients and patients daily. BrightSpring has consistently demonstrated strong and industry-leading quality metrics across its services lines, while improving the health and quality of life for high-need individuals and reducing overall healthcare system costs.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect our current views with respect to, among other things, our operations and financial performance. Forward-looking statements include all statements that are not historical facts. These forward-looking statements may relate to matters which include, but are not limited to, industries, business strategy, goals and expectations concerning our market position, future operations, margins, profitability, capital expenditures, liquidity and capital resources and other financial and operating information. In some cases, we have used words such as "anticipate," "assume," "believe," "continue, " "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "future," "will," "seek," "foreseeable," "target," "guidance," the negative version of these words, or similar terms and phrases to identify these forward-looking statements.
The forward-looking statements are based on management's current expectations and are not historical facts or guarantees of future performance. The forward-looking statements relate to the future and are therefore subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify. Our expectations, beliefs, and projections are expressed in good faith and we believe there is a reasonable basis for them. However, there can be no assurance that management's expectations, beliefs, and projections will result or be achieved. Actual results may differ materially from these expectations due to changes in global, regional, or local economic, business, competitive, market, regulatory, and other factors, many of which are beyond our control. We believe that these factors include but are not limited to the following:
-- our operation in a highly competitive industry;
-- our inability to maintain relationships with existing patient referral
sources or establish new referral sources;
-- changes to Medicare and Medicaid rates or methods governing Medicare and
Medicaid payments for our services;
-- cost containment initiatives of third-party payors, including
post-payment audits;
-- the implementation of alternative payment models and the transition of
Medicaid and Medicare beneficiaries to managed care organizations may
limit our market share and could adversely affect our revenues;
-- changes in the case mix of patients, as well as payor mix and payment
methodologies, and decisions and operations of third-party organizations;
-- our reliance on federal and state spending, budget decisions, and
continuous governmental operations which may fluctuate under different
political conditions;
-- changes in drug utilization and/or pricing, PBM contracts, and Medicare
Part D/Medicaid reimbursement, which may negatively impact our
profitability;
-- changes in our relationships with pharmaceutical suppliers, including
changes in drug availability or pricing;
-- reliance on the continual recruitment and retention of nurses,
pharmacists, therapists, caregivers, direct support professionals, and
other qualified personnel, including senior management;
-- compliance with or changes to federal, state, and local laws and
regulations that govern our employment practices, including minimum wage,
living wage, and paid time-off requirements;
-- fluctuation of our results of operations on a quarterly basis;
-- harm caused by labor relation matters;
-- limitations in our ability to control reimbursement rates received for
our services if we are unable to maintain or reduce our costs to provide
such services;
-- delays in collection or non-collection of our accounts receivable,
particularly during the business integration process;
-- failure to manage our growth effectively, which may inhibit our ability
to execute our business plan, maintain high levels of service and
satisfaction or adequately address competitive challenges;
-- our ability to identify, successfully complete and manage acquisitions,
joint ventures, divestitures and other significant transactions and
strategic initiatives;
-- our ability to continue to provide consistently high quality of care;
-- maintenance of our corporate reputation or the emergence of adverse
publicity, including negative information on social media or changes in
public perception of our services;
-- contract continuance, expansion and renewal with our existing customers,
including renewals at lower fee levels, customers declining to purchase
additional services from us, or reduction in the services received from
us pursuant to those contracts;
-- effective investment in, implementation of improvements to and proper
maintenance of the uninterrupted operation and data integrity of our
information technology and other business systems;
-- security breaches, loss of data, and other disruptions, which could
compromise sensitive business or patient information; cause a loss of
confidential patient data, employee data or personal information; or
prevent access to critical information and thereby expose us to liability,
litigation, and federal and state governmental inquiries and damage our
reputation and brand;
-- risks related to credit card payments and other payment methods;
-- potential substantial malpractice or other similar claims;
-- various risks related to governmental inquiries, regulatory actions, and
whistleblower and other lawsuits, which may not be entirely covered by
insurance;
-- our current insurance program, which may expose us to unexpected costs,
particularly if we incur losses not covered by our insurance or if claims
or losses differ from our estimates;
-- factors outside of our control, including those listed, which have
required and could in the future require us to record an asset impairment
of goodwill;
-- a pandemic, epidemic, or outbreak of an infectious disease;
-- inclement weather, natural disasters, acts of terrorism, riots, civil
insurrection or social unrest, looting, protests, strikes, or street
demonstrations;
-- our inability to adequately protect our intellectual property rights;
-- risks related to our compliance with our regulatory framework;
-- the significant interests of KKR Stockholder may conflict with our
stockholders' interests in the future;
-- our substantial indebtedness;
-- significant changes in tax or trade policies, tariffs, or trade relations
between the United States and other countries, such as the imposition of
unilateral tariffs on imported products, including impacts on imported
drug products, which could result in supply chain disruptions and
significant increases in costs; and
-- fluctuations in the amount and frequency of repurchases of our common
stock.
The forward-looking statements included in this press release are made only as of the date of this press release, and we undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as required by law. These factors should not be construed as exhaustive, and should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, our actual results may vary in material respects from those projected in these forward-looking statements. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Our forward- looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures, investments, or other strategic transactions we may make.
For additional information on these and other factors that could cause BrightSpring's actual results to differ materially from expected results, please see our filings with the Securities and Exchange Commission (the "SEC"), which are accessible on the SEC's website at www.sec.gov.
Non-GAAP Financial Measures
This press release contains "non-GAAP financial measures," including "EBITDA," "Adjusted EBITDA," and "Adjusted EPS," which are financial measures that either exclude or include amounts that are not excluded or included in the most directly comparable measures calculated and presented in accordance with accounting principles generally accepted in the United States, or GAAP.
EBITDA, Adjusted EBITDA, and Adjusted EPS have been presented in this release as supplemental measures of financial performance that are not required by, or presented in accordance with, GAAP, because we believe they assist investors and analysts in comparing our operating performance across reporting periods on a consistent basis by excluding items that we do not believe are indicative of our core operating performance. Management also believes that these measures are useful to investors in highlighting trends in our operating performance, while other measures can differ significantly depending on long-term strategic decisions regarding capital structure, the tax jurisdictions in which we operate and capital investments. Management uses EBITDA, Adjusted EBITDA, and Adjusted EPS to supplement GAAP measures of performance in the evaluation of the effectiveness of our business strategies, to make budgeting decisions, to establish and award discretionary annual incentive compensation, and to compare our performance against that of other peer companies using similar measures.
Management supplements GAAP results with non-GAAP financial measures to provide a more complete understanding of the factors and trends affecting the business than GAAP results alone. EBITDA, Adjusted EBITDA, and Adjusted EPS are non-GAAP measures of our financial performance and should not be considered as an alternative to net income as a measure of financial performance or any other performance measures derived in accordance with GAAP. Additionally, these measures are not intended to be a measure of free cash flow available for management's discretionary use as they do not consider certain cash requirements such as tax payments, debt service requirements, total capital expenditures, and certain other cash costs that may recur in the future.
(MORE TO FOLLOW) Dow Jones Newswires
May 01, 2026 06:00 ET (10:00 GMT)
Comments